Other3

Bolt Biotherapeutics, Inc.

Total Value

Filing Date

Nov 6, 2026

1 transactions

Trade Summary

On Nov 6, 2026, Coastlands Capital LP, 10% Owner, reported $0 of Bolt Biotherapeutics, Inc. (BOLT) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Coastlands Capital LP
Role: 10% Owner
Location: SAN FRANCISCO, CA

Filing Details

Filing Date: Nov 6, 2026
Transaction Date: Nov 6, 2026
Accession Number: 0001104659-26-124005
Form Type: 3

Want live alerts when Coastlands Capital LP trades again?

Download Insider Trades to track BOLT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 3 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.
(F2)Following stockholder approval of the conversion of Series D Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series D Preferred Stock"), into shares of Common Stock and, to the extent deemed necessary or advisable, an increase in the number of authorized shares of Common Stock, each share of Series D Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations. The Series D Preferred Stock has no expiration date. Coastlands may not convert such shares if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.
(F3)The warrants to purchase shares of the Issuer's common stock (the "Warrants") become exercisable following the automatic conversion of the Series D Preferred Stock into Common Stock upon receipt of the requisite stockholder approval, and expire on the earlier of (i) 30 days following the Issuer's first public disclosure of top-line results from the first-in-human clinical data from its Program 2 Phase 1 (IL-31 bispecific) and (ii) June 30, 2028. Coastlands may not exercise the Warrants if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Coastlands Capital LP

(Last)

(First)

(Middle)

601 CALIFORNIA STREET, SUITE 1210

(Street)

SAN FRANCISCO

94108

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/06/2026

3. Issuer Name and Ticker or Trading Symbol
Bolt Biotherapeutics, Inc. [ BOLT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	412,416	I	By Coastlands Capital LP⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series D Non-Voting Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	1,166,275	⁽²⁾	I	By Coastlands Capital LP⁽¹⁾
Warrant	⁽³⁾	⁽³⁾	Common Stock	583,138	$8.5743	I	By Coastlands Capital LP⁽¹⁾

Explanation of Responses:

1. Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 3 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein.

2. Following stockholder approval of the conversion of Series D Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series D Preferred Stock"), into shares of Common Stock and, to the extent deemed necessary or advisable, an increase in the number of authorized shares of Common Stock, each share of Series D Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations. The Series D Preferred Stock has no expiration date. Coastlands may not convert such shares if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.

3. The warrants to purchase shares of the Issuer's common stock (the "Warrants") become exercisable following the automatic conversion of the Series D Preferred Stock into Common Stock upon receipt of the requisite stockholder approval, and expire on the earlier of (i) 30 days following the Issuer's first public disclosure of top-line results from the first-in-human clinical data from its Program 2 Phase 1 (IL-31 bispecific) and (ii) June 30, 2028. Coastlands may not exercise the Warrants if Coastlands, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

Remarks:

Exhibit 99.1 - Agreement Regarding Joint Filing of Statement

	/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital LP	11/06/2026
	/s/ Mark Shamia, Chief Operating Officer of the General Partner of Coastlands Capital Partners LP	11/06/2026
	/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital GP LLC	11/06/2026
	/s/ Mark Shamia, Chief Operating Officer of Coastlands Capital LLC	11/06/2026
	/s/ Matthew D. Perry	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 as rendered by the SEC from accession 0001104659-26-124005.

Bolt Biotherapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Want live alerts when Coastlands Capital LP trades again?

Footnotes

SEC Form 3

SEC Filing

SEC Form 3